CDKN1A and colorectal carcinoma: These findings demonstrate that inhibiting EZH2 and its downstream activation of pathways, such as inactivating p21cip1-Wnt/β-catenin signaling pathway was effective in eliminating CCS-like cells and reducing CRC progression.